Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business.

We recently reported significant progress on several fronts:

• In February 2025, we reported positive Phase 2 study data evaluating our ifetroban product candidate in patients with Duchenne muscular dystrophy. That breakthrough had a dramatic impact on our share price and trading volumes. It’s the first time we have seen investors recognize the value of our development capabilities and pipeline.
• Our potent antibiotic Vibativ® received approval by the regulatory authorities in China – the world’s second largest pharmaceutical market.
• We posted strong fourth quarter top-line results with net revenues at $10.4 million, which represented a $1.1 million or 11.6% increase over the prior year period. Strong international sales contributed to this growth.

Additionally, there were a series of key developments during 2024 that enabled us to make significant progress in our newly refined mission – working together to provide unique products that improve the quality of patient care.

2024 was a transformative year for Cumberland, marked by expanded product labeling, key FDA designations and significant new study publications that underscore our commitment to improving patient care. These achievements were made possible by the dedication of our outstanding team.

As we move into 2025, we remain focused on driving growth, delivering value to our stakeholders and advancing our mission. I look forward to continuing to share our progress throughout the year.